RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Business Wire
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regenxbio issued a press release on January 28, 2026, announcing that the FDA “placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The Company added, "the FDA also placed a clinical hold on RGX-121, for the treatment of MPS II, also known as Hunter Syndrome, citing the similarities in products, study populations, and shared risk between the clinical studies."
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNXGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNXPR Newswire
- Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA ActionPR Newswire
- REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- REGENXBIO (NASDAQ:RGNX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.MarketBeat
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 1/29/26 - Form 4
- RGNX's page on the SEC website